350
Participants
Start Date
February 25, 2021
Primary Completion Date
April 30, 2023
Study Completion Date
August 30, 2023
IMP7068
To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
RECRUITING
Chang Gung Medical Foundation - Linkou Branch, Taoyuan District
RECRUITING
National Cheng Kung University Hospital, Tainan City
RECRUITING
Emory University Hospital, Atlanta
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
China Medical University Hospital, Taichung
RECRUITING
University of Kansas Clinical Research Center, Fairway
RECRUITING
Chi Mei Hospital, Liouying, Tainan City
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
Next Oncology, San Antonio
WITHDRAWN
Comprehensive Cancer Centers of Nevada, Las Vegas
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Wuhan Union Hospital, Wuhan
RECRUITING
West China 2nd University Hospital, Chengdu
NOT_YET_RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
National Taiwan University Hospital, Taipei
Lead Sponsor
Collaborators (1)
Covance
INDUSTRY
Impact Therapeutics, Inc.
INDUSTRY